Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition of glycopyrrolate and a beta2-agonist

一种组合物、激动剂的技术，应用在炎性或阻塞性气道疾病,预防和/或治疗呼吸性,慢性阻塞性肺病领域，能够解决老年人骨密度不利影响、皮质类固醇使用限制等问题

Inactive Publication Date: 2014-01-08
CIPLA LTD
View PDF15 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] However, the use of corticosteroids has been limited due to possible side effects associated with their use, including suppression of the hypothalamic-pituitary-adrenal (HPA) axis, adverse effects on bone growth in children and bone density in the elderly effects, ophthalmic complications (cataract formation and glaucoma), and skin atrophy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition of glycopyrrolate and a beta2-agonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0139] process:

[0140] 1) Homogenize fluticasone furoate, glycopyrronium and tiotropium bromide with a portion of HFA.

[0141] 2) Transfer the suspension obtained in step 1 to a mixing vessel and add the remaining amount of HFA.

[0142] 3) The resulting suspension was mixed, recycled and filled into pre-crimped aluminum cans.

Embodiment 2

[0145] process:

[0146] 1) Fluticasone furoate, indacaterol and glycopyrronium were homogenized with lactose and a portion of HFA.

[0147] 2) Transfer the suspension obtained in step 1 to a mixing vessel and add the remaining amount of HFA.

[0148] 3) The resulting suspension was mixed, recycled and filled into pre-crimped aluminum cans.

Embodiment 3

[0151] process:

[0152] 1) Dissolve PVP in PEG and a partial amount of HFA134A or HFA227.

[0153] 2) Transfer the solution obtained in step 1 to a mixing vessel.

[0154] 3) Fluticasone furoate, indacaterol and glycopyrronium were homogenized with a portion of HFA.

[0155] 4) Transfer the suspension obtained in step 3 to a mixing vessel and add the remainder of HFA.

[0156] 5) The entire resulting suspension was mixed, recycled and filled into pre-crimped aluminum cans.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to pharmaceutical compositions for inhalation comprising glycopyrrolate, a beta2-agonist, and optionally an inhaled corticosteroid; 103501776to a process for preparing such compositions and to the use of such compositions for the prevention and / or treatment of respiratory, inflammatory or obstructive airway disease.

Description

technical field [0001] The present invention relates to pharmaceutical compositions for inhalation comprising one or more bronchodilators and optionally an inhaled corticosteroid. Also provided is a preparation method of the composition and its use for preventing and / or treating respiratory, inflammatory or obstructive airway diseases, especially chronic obstructive pulmonary disease. Background technique [0002] Chronic obstructive pulmonary disease (COPD) is a serious respiratory disorder with increasing prevalence worldwide. In India, the estimated prevalence is about 12.36 million. It is currently the fourth leading cause of death in the UK and US and is expected to rank third in global disease impact by 2020. [0003] COPD is a preventable and treatable disease state characterized by airflow limitation that is not fully reversible. Airflow obstruction is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/138A61K31/167A61K31/40A61K31/4704A61K31/538A61K31/57A61K31/58A61P11/06A61P11/00
CPCA61K31/538A61K31/167A61K31/4704A61K31/135A61K31/58A61K31/138A61K31/56A61K31/57A61K31/40A61K9/008A61P11/00A61P11/06A61P11/08A61P43/00A61K2300/00A61K9/0073A61K9/0075A61K9/0078A61K47/06A61K47/26
Inventor G·马尔霍特拉S·M·普兰达里
Owner CIPLA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com